By Patrick Wingrove and Ahmed Aboulenein (Reuters) -Eli Lilly plans to spend at least $27 billion to build four new ...

The company is doubling plans for capital spending on U.S. factories as President Donald Trump pressures the pharma industry ...

United Health Group, the largest U.S. health insurer by enrollees, was under pressure after Sen. Chuck Grassley, chairman of the Senate Judiciary Committee, sent the conglomerate's chief executive, ...

Coverage complications are not unusual in the U.S. healthcare system. But the challenge is magnified for these obesity ...

Wave goodbye to the Part D "donut hole" and hello to a $2,000 cap on the amount you'll pay for medications. But other changes ...

U.S. pharmaceutical giant Eli Lilly (LLY) is lowering the cost of its blockbuster weight loss medication Zepbound in an effort to reach more ...

Eli Lilly is offering higher-dose vials through its direct-to-consumer website, LillyDirect, which started offering lower ...

Supplies of high-demand obesity treatments are improving, but that doesn’t mean they're easier to get. Many employers and ...

She has extensive experience in health policy, Medicare Advantage and the... Editorial Note: We earn a commission from partner links on Forbes Advisor. Commissions do not affect our editors ...

Commissions do not affect our editors' opinions or evaluations. People who become eligible for Medicare coverage have two primary enrollment choices: Original Medicare and Medicare Advantage.

On Dec. 20, 2024, the FDA approved Zepbound for the treatment of moderate to severe ... That depends on what insurance you have and why the medication was prescribed. Medicare Part D will cover GLP-1 ...